Safilo Group SpASAFLF 62 EBITDA Margin % is 8.27% as of Dec. 2025, which is 58% above its 10-year median of 5.25. GuruFocus rates SAFLF with a GF Score™ of 62/100 and a GF Value™ of $1.24 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Safilo Group SpA ranks better than 58.46% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Safilo Group SpA's EBITDA for the
six
months ended in Dec. 2025 was $43 Mil. Safilo Group SpA's Revenue for the
six
months ended in Dec. 2025 was $522 Mil. Therefore, Safilo Group SpA's EBITDA margin for the quarter that ended in Dec. 2025 was 8.27%.
Safilo Group SpA (OTCPK:SAFLF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Safilo Group SpA EBITDA Margin % Related Terms
Safilo Group SpA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Safilo Group SpA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAFLF vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Safilo Group SpA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Safilo Group SpA EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Safilo Group SpA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Safilo Group SpA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Safilo Group SpA (SAFLF) has a EBITDA Margin % of 8.27% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Safilo Group SpA and its competitors. This is 58% above median its historical median of 5.25. According to the industry distribution chart, Safilo Group SpA ranks #339 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 41.5%.
Is Safilo Group SpA's EBITDA Margin % too high?
Safilo Group SpA's current EBITDA Margin % of 8.27% is 58% above median its 10-year median of 5.25. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Safilo Group SpA's value of 8.27% is 10.6% above this industry median. Based on the distribution chart, Safilo Group SpA ranks #339 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Safilo Group SpA has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Safilo Group SpA's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Safilo Group SpA ranks #339 out of 816 companies for EBITDA Margin %. This puts Safilo Group SpA in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Safilo Group SpA's value of 8.27% is 10.6% above this benchmark. While the company's 10-year median is 5.25 vs. the industry median of 7.48, Safilo Group SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Safilo Group SpA's current EBITDA Margin % of 8.27% is 10.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Safilo Group SpA and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Safilo Group SpA's current EBITDA Margin % is 8.27%, which is 58% above median its own 10-year median of 5.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Safilo Group SpA stock overvalued right now?
Based on GuruFocus' analysis, Safilo Group SpA (SAFLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.24, compared to a current price of $2.01 — trading 62.1% above its estimated fair value. The current EBITDA Margin % is 8.27%, which is 58% above median its 10-year median of 5.25 and 10.6% above the Medical Devices & Instruments industry median of 7.48. Safilo Group SpA's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Safilo Group SpA (SAFLF), the current EBITDA Margin % is 8.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Safilo Group SpA (SAFLF) Overvalued in 2026?
Based on GuruFocus' analysis, Safilo Group SpA stock appears to be overvalued.
The current stock price of $2.01 is trading 62.1% above its estimated GF Value™ of $1.24.
GuruFocus considers Safilo Group SpA to be Significantly Overvalued.
Key valuation signals for SAFLF:
EBITDA Margin %: 8.27% (58% above median its 10-year median of 5.25)
GF Value™: $1.24 vs. price of $2.01 (62.1% above fair value)
Industry Position: 10.6% above the Medical Devices & Instruments median (#339 of 816)
No single metric tells the full story. See the SAFLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Safilo Group SpA makes sunglasses and prescription eyewear. It is engaged in design, production, and wholesale distribution of its products through a network of independent distributors and commercial subsidiaries. Its products are sold through the Carrera, Smith, Polaroid and Oxydo brands, as well as a range of other licensed brands. The company operates solely through the wholesale segment channels and divides itself into the following four geographical segments: Europe, America, and Asia. The company earns the majority of its revenue from the Europe business segment.
62GF Score
Get the complete analysis for SAFLF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAFLF has been successfully added to your 
